Here's Why ResMed (RMD) is a Strong Growth Stock

The article details Zacks Premium's proprietary investment methodology, which combines the historically high-performing Zacks Rank (e.g., #1 stocks averaging +23.64% annual returns since 1988) with complementary Zacks Style Scores (Value, Growth, Momentum, and VGM) to identify optimal stock selections. This framework recommends combining top Zacks Ranks with A or B Style Scores for enhanced probability of success. ResMed (RMD) is highlighted as a compelling example; despite its current Zacks #3 (Hold) rank, its 'A' Growth and VGM Style Scores, coupled with a 13.7% projected earnings growth for the current fiscal year and recent upward analyst revisions for FY26, position it as a strong growth opportunity for investors.

Analysis

ResMed (RMD) is presented as a compelling investment case for growth-oriented investors, primarily based on its strong underlying fundamentals as measured by the Zacks rating system. Despite a neutral Zacks #3 (Hold) rank, the company's profile is significantly enhanced by its 'A' ratings for both its Growth Style Score and its overall VGM (Value, Growth, Momentum) Score. This positive outlook is substantiated by a forecast for 13.7% year-over-year earnings growth in the current fiscal year. Furthermore, forward-looking sentiment from analysts appears robust; for fiscal 2026, seven analysts have revised their earnings estimates upward within the last 60 days, causing the Zacks Consensus Estimate to increase by $0.43 to $10.86 per share. The company's operational consistency is underscored by a historical average earnings surprise of +4.5%, suggesting a pattern of outperformance against market expectations. The analysis posits that these strong, forward-looking growth indicators may outweigh the more cautious signal of its current 'Hold' rank.

Key Decisions for Investors

• Growth-focused investors should consider ResMed for their watchlist, as its 'A' rated Growth and VGM scores, combined with a 13.7% earnings growth forecast, suggest fundamental strength that may not be fully reflected in its neutral #3 (Hold) rank.
• Monitor the trend in analyst earnings revisions for fiscal 2026, as the recent upward movement by seven analysts is a key bullish catalyst highlighted in the report.
• Investors should weigh the conflicting signals of a neutral 'Hold' rank against the strong growth metrics, recognizing that a position in RMD is essentially a bet that its positive earnings trajectory will lead to future outperformance and a potential rank upgrade.